You just read:

Keryx Biopharmaceuticals Initiates Long-Term Study Component of Phase 3 Registration Program of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease on Dialysis

News provided by

Keryx Biopharmaceuticals, Inc.

Sep 29, 2010, 08:30 ET